drugset / Trial / NCT06416930
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Phase 2
Not yet recruiting
59 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Akesobio · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
Timeline
- Start
- 2024-06-20
- Primary completion
- 2027-06-20
- Completion
- 2029-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 30 mg | Oral |